Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283787 · ClinicalTrials.gov registry record · NA
Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT03283787 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 60 participants.
The verdict
NCT03283787, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
Interventions
- DEVICE Negative Pressure Wound Therapy
- DEVICE MicroMatrix® and Cytal™ Wound Matrix 2-Layer
- DEVICE MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-12-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283787
The ClinicalTrials.gov registry entry for NCT03283787 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Negative Pressure Wound Therapy is the first listed.
NCT03283787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283787 about?
NCT03283787 is a clinical study titled "Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries". The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
What is the current status of trial NCT03283787?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-04-01. Estimated completion is 2019-12-23.
What interventions are being tested in trial NCT03283787?
The interventions under investigation include: Negative Pressure Wound Therapy (DEVICE), MicroMatrix® and Cytal™ Wound Matrix 2-Layer (DEVICE), MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT (DEVICE).
Who is sponsoring clinical trial NCT03283787?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.